Logo image of GLPG.AS

GALAPAGOS NV (GLPG.AS) Stock Price, Quote, News and Overview

AMS:GLPG - Euronext Amsterdam - BE0003818359 - Common Stock - Currency: EUR

24.3  +0.42 (+1.76%)

GLPG.AS Quote, Performance and Key Statistics

GALAPAGOS NV

AMS:GLPG (5/2/2025, 5:35:15 PM)

24.3

+0.42 (+1.76%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High31.08
52 Week Low20
Market Cap1.60B
Shares65.90M
Float65.89M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)07-23 2025-07-23
IPO05-06 2005-05-06


GLPG.AS short term performance overview.The bars show the price performance of GLPG.AS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 10

GLPG.AS long term performance overview.The bars show the price performance of GLPG.AS in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of GLPG.AS is 24.3 EUR. In the past month the price increased by 2.67%. In the past year, price decreased by -11.49%.

GALAPAGOS NV / GLPG Daily stock chart

GLPG.AS Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 19.14 305.68B
1ABBV.MI ABBVIE INC 18.67 294.00B
AMG.DE AMGEN INC 14.09 132.07B
1GILD.MI GILEAD SCIENCES INC 23.08 116.51B
VX1.DE VERTEX PHARMACEUTICALS INC 1783.4 114.62B
GIS.DE GILEAD SCIENCES INC 13.4 113.73B
ARGX.BR ARGENX SE 378.68 35.15B
22UA.DE BIONTECH SE-ADR N/A 22.20B
IDP.DE BIOGEN INC 7.32 15.52B
0QF.DE MODERNA INC N/A 9.39B
1MRNA.MI MODERNA INC N/A 9.08B
AZT.OL ARCTICZYMES TECHNOLOGIES ASA 117.5 840.10M

About GLPG.AS

Company Profile

GLPG logo image Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 704 full-time employees. The company went IPO on 2005-05-06. The firm is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. The company develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. The company discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The firm acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.

Company Info

GALAPAGOS NV

Generaal De Wittelaan L11 A3

MALINES (MECHELEN) ANTWERPEN BE

Employees: 683

Company Website: https://www.glpg.com/

Investor Relations: https://www.glpg.com/investor-center

Phone: 3215342900

GALAPAGOS NV / GLPG.AS FAQ

What is the stock price of GALAPAGOS NV today?

The current stock price of GLPG.AS is 24.3 EUR. The price increased by 1.76% in the last trading session.


What is the ticker symbol for GALAPAGOS NV stock?

The exchange symbol of GALAPAGOS NV is GLPG and it is listed on the Euronext Amsterdam exchange.


On which exchange is GLPG.AS stock listed?

GLPG.AS stock is listed on the Euronext Amsterdam exchange.


What is the price forecast or stock price prediction for GALAPAGOS NV stock?

19 analysts have analysed GLPG.AS and the average price target is 30.95 EUR. This implies a price increase of 27.38% is expected in the next year compared to the current price of 24.3. Check the GALAPAGOS NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is GALAPAGOS NV worth?

GALAPAGOS NV (GLPG.AS) has a market capitalization of 1.60B EUR. This makes GLPG.AS a Small Cap stock.


How many employees does GALAPAGOS NV have?

GALAPAGOS NV (GLPG.AS) currently has 683 employees.


What are the support and resistance levels for GALAPAGOS NV (GLPG.AS) stock?

GALAPAGOS NV (GLPG.AS) has a support level at 21.16 and a resistance level at 23.99. Check the full technical report for a detailed analysis of GLPG.AS support and resistance levels.


Is GALAPAGOS NV (GLPG.AS) expected to grow?

The Revenue of GALAPAGOS NV (GLPG.AS) is expected to decline by -7.9% in the next year. Check the estimates tab for more information on the GLPG.AS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy GALAPAGOS NV (GLPG.AS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does GALAPAGOS NV (GLPG.AS) stock pay dividends?

GLPG.AS does not pay a dividend.


When does GALAPAGOS NV (GLPG.AS) report earnings?

GALAPAGOS NV (GLPG.AS) will report earnings on 2025-07-23.


What is the Price/Earnings (PE) ratio of GALAPAGOS NV (GLPG.AS)?

GALAPAGOS NV (GLPG.AS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.43).


GLPG.AS Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to GLPG.AS. When comparing the yearly performance of all stocks, GLPG.AS turns out to be only a medium performer in the overall market: it outperformed 51.06% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

GLPG.AS Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to GLPG.AS. The financial health of GLPG.AS is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GLPG.AS Financial Highlights

Over the last trailing twelve months GLPG.AS reported a non-GAAP Earnings per Share(EPS) of -2.43. The EPS decreased by -157.48% compared to the year before.


Industry RankSector Rank
PM (TTM) 25.35%
ROA 1.79%
ROE 2.56%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-259.22%
Sales Q2Q%11.56%
EPS 1Y (TTM)-157.48%
Revenue 1Y (TTM)14.99%

GLPG.AS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 49% to GLPG.AS. The Buy consensus is the average rating of analysts ratings from 19 analysts.

For the next year, analysts expect an EPS growth of -198.38% and a revenue growth -7.9% for GLPG.AS


Ownership
Inst Owners48.62%
Ins Owners0.01%
Short Float %N/A
Short RatioN/A
Analysts
Analysts49.47
Price Target30.95 (27.37%)
EPS Next Y-198.38%
Revenue Next Year-7.9%